RxDoctor Payments Data

Hector Caballero, MD

Neurology · Birmingham, ALNPI 1780674762

Payments from drug & device makers

$1,966in general payments, 2019–2025

Across 120 payments — averaging $16.38 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$266
  • Pfizer$265
  • Eisai Inc.$205
  • Supernus Pharmaceuticals, Inc.$199
  • Biohaven Pharmaceutical Holding Company Ltd.$192
  • Amgen$192
  • plus $647 from 15 others

What the payments were for

  • Food & beverage$1,93999%
  • Education$271%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,966 in reported general payments places this provider in the 40th percentile of 255 neurology providers in Alabama.

See all neurology providers in Alabama

Medicare billing

Part B allowed, 2024
$100,683
Medicare patients
149
Services billed
1,209

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
TecfideraDimethyl Fumarate12$96,669
Aimovig AutoinjectorErenumab-Aooe29$26,790
Lacosamide82$22,893
Emgality SyringeGalcanezumab-Gnlm11$18,180
Sumatriptan Succinate73$6,870
Pregabalin114$4,975
Memantine Hcl95$4,425
Duloxetine Hcl97$3,928
Aripiprazole12$3,259
RizatriptanRizatriptan Benzoate81$3,221
Gabapentin113$2,226
Pyridostigmine Bromide21$2,109
Naratriptan Hcl45$2,069
Topiramate143$2,051
Levetiracetam69$2,009

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
BiogenTecfidera$22$96,66912 claims
Amneal Pharmaceuticals LLCPyridostigmine Bromide$45$2,10921 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 255 neurology providers in Alabama.

Other neurology in Birmingham

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →